Cargando…
Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
A 39-year-old male with decreased visual acuity and extensive macular hemorrhage and edema secondary to a hemiretinal vein occlusion was treated with multiple intravitreal injections of bevacizumab 1.25 mg every four to six weeks for over one year. Treatment outcomes were assessed by visual acuity a...
Autores principales: | Yalamanchi, Shalini, Flynn, Harry W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206123/ https://www.ncbi.nlm.nih.gov/pubmed/22069354 http://dx.doi.org/10.2147/OPTH.S23698 |
Ejemplares similares
-
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Gutiérrez, Juan Carlos Mesa, et al.
Publicado: (2008) -
Significant vision improvement and successful prevention of recurrence by electroacupuncture in hemiretinal vein occlusion combined with macular edema: A case report
por: Yan, Yan, et al.
Publicado: (2021) -
Diabetic papillopathy with macular edema treated with intravitreal bevacizumab
por: Al-Hinai, Ahmed S., et al.
Publicado: (2011) -
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska, Biljana, et al.
Publicado: (2017) -
Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
por: Demir, Mehmet, et al.
Publicado: (2011)